Here are the 10-Q quarterly reports from SBC Medical Group Holdings Incorporated Warrants (SBCWW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SBCWW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBCWW filings page.
SBC Medical Group Holdings Incorporated reported solid results for the quarter ended June 30, 2026. Total revenues were $49.19 million, up from $43.36 million a year earlier, driven mainly by related-party revenues. Quarterly income from operations rose to $18.96 million from $14.55 million, and net income attributable to the company increased to $10.69 million from $2.46 million, with basic and diluted EPS of $0.10.
For the first six months of 2026, total revenues were $92.25 million versus $90.69 million in 2025, while net income attributable to the company was $22.00 million compared with $23.96 million. Operating cash flow improved markedly, moving from a use of $6.41 million in the prior-year period to positive cash provided of $31.74 million. Cash and cash equivalents increased to $184.31 million as of June 30, 2026, against total bank and other borrowings of $37.75 million, supporting a total asset base of $406.66 million and stockholders’ equity of $279.92 million.
The company recorded a $0.57 million loss from its equity method investment in OT Midco and a significant foreign currency translation loss of $9.57 million, which reduced accumulated other comprehensive income. During the quarter, SBC deconsolidated its variable interest entity AMM; the CEO’s repayment of AMM’s obligations generated a $3.65 million deemed capital contribution, boosting additional paid-in capital. Management also introduced two reportable segments (SBC core and Waqoo) and continues to highlight heavy reliance on a small number of major customers.
SBC Medical Group Holdings reported first-quarter 2026 total revenue of $43.1 million, down from $47.3 million a year earlier, as related-party revenues softened while third-party revenues grew. Gross profit declined to $30.3 million from $37.7 million, reflecting higher cost of revenues.
Income from operations fell to $17.7 million from $24.2 million. Net income attributable to SBC decreased to $11.3 million versus $21.5 million, and basic and diluted EPS declined to $0.11 from $0.21, partly because the prior-year period included a sizable gain on redemption of life insurance policies.
Despite lower earnings, operating cash flow strengthened to $9.2 million from $1.9 million, helped by working capital movements and lower income tax payments. Cash and cash equivalents rose to $167.3 million as of March 31, 2026, and total assets reached $388.0 million with total liabilities of $117.6 million. Stockholders’ equity increased to $270.4 million. Weighted average shares outstanding were 102,576,943 for the quarter, and net income included modest non-controlling interest allocations.